PLIANT THERA.INC.DL-0001
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more
PLIANT THERA.INC.DL-0001 (9PT) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PLIANT THERA.INC.DL-0001 (9PT) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PLIANT THERA.INC.DL-0001 - Net Assets Trend (None–None)
This chart illustrates how PLIANT THERA.INC.DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PLIANT THERA.INC.DL-0001 (None–None)
The table below shows the annual net assets of PLIANT THERA.INC.DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PLIANT THERA.INC.DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PLIANT THERA.INC.DL-0001 Competitors by Market Cap
The table below lists competitors of PLIANT THERA.INC.DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620
|
$57.77 Million |
|
Elixir Energy Ltd
AU:EXR
|
$57.78 Million |
|
Intellistake Technologies Corp.
F:E41
|
$57.79 Million |
|
GATELEY (HLDGS) LS -10
F:5I2
|
$57.81 Million |
|
Türk Traktör ve Ziraat Makineleri A.S
PINK:TTRKF
|
$57.71 Million |
|
UHT Unitech Co., Ltd.
TWO:6618
|
$57.70 Million |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
$57.66 Million |
|
TuHURA Biosciences Inc
NASDAQ:HURA
|
$57.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PLIANT THERA.INC.DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PLIANT THERA.INC.DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PLIANT THERA.INC.DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PLIANT THERA.INC.DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PLIANT THERA.INC.DL-0001 (9PT) | €- | N/A | N/A | $57.71 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |